Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
X-TROZINE L.A. vs ACTAHIST
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
X-TROZINE L. A. is a piperazine derivative that acts as a centrally acting alpha-2 adrenergic agonist, reducing sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and lowered blood pressure.
Antihistamine; binds to histamine H1 receptors, blocking the effects of histamine; also exhibits anticholinergic and mild sedative properties.
Hypertension (extended-release formulation),Off-label: Management of opioid withdrawal symptoms
Symptomatic relief of allergic rhinitis,Urticaria,Off-label: motion sickness,Off-label: insomnia
250 mg orally once daily. May be increased to 500 mg once daily if needed.
1.34 mg (one capsule) orally twice daily.
12-15 hours; prolonged in renal impairment (up to 30 hours in Cr Cl <30 m L/min).
6.9 ± 1.7 hours in adults; prolonged to 12-18 hours in elderly or patients with hepatic impairment, requiring dosing interval adjustment.
Primarily hepatic via CYP3A4; metabolites include inactive glucuronides.
Hepatic metabolism via CYP450 enzymes (primarily CYP3A4 and CYP2D6); major metabolite is inactive.
Primarily renal (70-80% as unchanged drug), with 20-30% fecal via biliary excretion.
Primarily renal (approximately 85% as unchanged drug and metabolites) and fecal (15%) via biliary elimination.
95-98% bound to albumin and alpha-1-acid glycoprotein.
92% bound to albumin.
0.8-1.2 L/kg, indicating extensive tissue distribution.
0.9 ± 0.3 L/kg, indicating extensive extravascular distribution.
Oral: 40-60% (due to first-pass metabolism); IM: 80-90%.
Oral: 68% ± 12% due to first-pass metabolism.
Cr Cl 30-89 m L/min: 250 mg every 48 hours. Cr Cl <30 m L/min: 250 mg every 72 hours. Hemodialysis: 250 mg post-dialysis three times weekly.
No dose adjustment required for mild to moderate renal impairment. Safety not established for severe impairment (GFR <30 m L/min).
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 250 mg once daily. Child-Pugh C: use is not recommended.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended for severe hepatic impairment (Child-Pugh C).
Children ≥2 years: 5 mg/kg orally once daily, maximum 250 mg. Adolescents: 250 mg once daily.
Not indicated for pediatric patients under 12 years of age. Safety and efficacy not established.
Initiate at 125 mg once daily; titrate cautiously. Monitor renal function and adjust per renal guidelines.
No specific dose adjustment recommended; monitor for increased anticholinergic effects and cognitive impairment.
X-TROZINE L. A. carries a black box warning for severe hypotension and syncope, especially on initial dosing or dose escalation; risk of orthostatic hypotension is increased with concomitant use of diuretics or beta-blockers.
None.
May cause bradycardia and heart block; caution in patients with pre-existing cardiac conduction abnormalities. Avoid abrupt discontinuation due to risk of rebound hypertension. Use with caution in patients with renal impairment (dose adjustment recommended). May cause drowsiness and impaired cognitive function.
May cause drowsiness; caution when driving or operating machinery. Avoid alcohol. Use with caution in patients with narrow-angle glaucoma, prostatic hyperplasia, or urinary retention. Geriatric patients more sensitive to anticholinergic effects. Pediatric patients <6 years: not recommended.
Hypersensitivity to piperazine derivatives; severe bradycardia or sick sinus syndrome without pacemaker; concurrent use of MAO inhibitors; history of hepatic encephalopathy.
Hypersensitivity to any component. Newborns or premature infants. Breastfeeding (contraindicated due to risk of adverse effects in infants). Concomitant use with MAOIs.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and may increase drug levels, raising risk of side effects. Take with or without food; if GI upset occurs, take with a small meal.
Avoid high-tyramine foods (aged cheese, cured meats, fermented products) if taking MAOIs. Grapefruit juice may increase phenylephrine absorption; limit intake.
First trimester: Associated with increased risk of neural tube defects (NTDs) and oral clefts based on animal studies and limited human data; second and third trimester: Risk of fetal growth restriction and oligohydramnios due to potential effects on placental perfusion.
ACTAHIST (brompheniramine/phenylephrine) pregnancy category C. Inadequate human data; animal studies show no malformations at therapeutic doses. First trimester: theoretical risk from vasoconstrictive effects (phenylephrine) possibly reducing uterine blood flow; avoid if possible. Second/third trimester: phenylephrine may cause fetal hypoxia via placental vasoconstriction; use only if benefit outweighs risk. No known structural teratogenicity.
Excreted into breast milk; M/P ratio approximately 0.8. Avoid breastfeeding due to potential adverse effects on infant neurodevelopment and risk of hypotonia.
Brompheniramine is excreted in breast milk in small amounts; M/P ratio not established. Phenylephrine has minimal excretion. Due to anticholinergic effects, may reduce milk production or cause sedation in infants. Use caution; prefer non-sedating alternatives if possible.
Increased clearance due to expanded plasma volume and enhanced hepatic metabolism; dose may need to be increased by 30-50% in the second and third trimesters; monitor therapeutic drug levels.
No specific pharmacokinetic studies. Increased plasma volume and renal clearance in pregnancy may reduce drug levels, but efficacy threshold remains. No dose adjustment recommended; use the lowest effective dose for shortest duration due to potential risks.
X-TROZINE L. A. is a long-acting antihistamine used for allergic rhinitis and chronic urticaria. Its peak effect occurs 6-12 hours post-dose; avoid concurrent use with CNS depressants due to additive sedation. In elderly patients, reduce dose to prevent anticholinergic side effects like urinary retention and blurred vision. Monitor liver function in patients with hepatic impairment as metabolism is hepatic via CYP3A4.
Actahist is a combination antihistamine-decongestant (chlorpheniramine/phenylephrine). Avoid in patients with hypertension, severe coronary artery disease, or MAOI use. Monitor for sedation and urinary retention, especially in elderly males with BPH.
Take exactly as prescribed, usually once daily; do not crush or chew the extended-release tablet.,May cause drowsiness; avoid driving or operating heavy machinery until you know how it affects you.,Avoid alcohol and other sedatives to prevent increased drowsiness.,Notify your doctor if you experience vision changes, difficulty urinating, or rapid heartbeat.,Store at room temperature away from moisture and heat.
Take with food or milk to reduce stomach upset.,Avoid alcohol and CNS depressants as they can increase drowsiness.,Do not drive or operate machinery until you know how this medication affects you.,Contact your doctor if you experience chest pain, rapid heartbeat, or difficulty urinating.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about X-TROZINE L.A. vs ACTAHIST, answered by our medical review team.
X-TROZINE L.A. is a Antihistamine that works by X-TROZINE L. A. is a piperazine derivative that acts as a centrally acting alpha-2 adrenergic agonist, reducing sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and lowered blood pressure.. ACTAHIST is a Antihistamine that works by Antihistamine; binds to histamine H1 receptors, blocking the effects of histamine; also exhibits anticholinergic and mild sedative properties.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between X-TROZINE L.A. and ACTAHIST depend on the specific clinical indication. These are both Antihistamine agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of X-TROZINE L.A. is: 250 mg orally once daily. May be increased to 500 mg once daily if needed.. The standard adult dose of ACTAHIST is: 1.34 mg (one capsule) orally twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between X-TROZINE L.A. and ACTAHIST in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. X-TROZINE L.A. is classified as Category C. First trimester: Associated with increased risk of neural tube defects (NTDs) and oral clefts based on animal studies and limited human data; second and third trimester: Risk of fe. ACTAHIST is classified as Category C. ACTAHIST (brompheniramine/phenylephrine) pregnancy category C. Inadequate human data; animal studies show no malformations at therapeutic doses. First trimester: theoretical risk f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.